Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership. The expanded agreement enables Fisher Scientific to distribute Harvard Bioscience's pumps, spectrophotometers, and BTX electroporation systems throughout the U.S.
The strategic expansion gives Harvard Bioscience access to hundreds of Fisher Scientific sales representatives and their extensive U.S. distribution network. The partnership will offer both established product lines and emerging technologies, including the Mesh MEA for advanced organoid research. This collaboration aims to enhance customer experience through streamlined ordering, faster delivery, and localized support.
Positive
- Access to hundreds of Fisher Scientific sales representatives in the U.S. market
- Expanded distribution network through partnership with one of world's largest scientific suppliers
- Streamlined ordering and faster delivery capabilities for customers
- Enhanced market reach for both established products and emerging technologies
Negative
- None.
Details
News Market Reaction – HBIO
On Sep 16, the day this news came out, HBIO closed 10.33% above the previous close.
Data tracked by StockTitan Argus for the Sep 16 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Strategic expansion with trusted partner enhances customer reach
HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world’s largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific will now offer Harvard Bioscience pumps, spectrophotometers, and BTX electroporation systems in the United States, complementing the existing distribution agreement in Europe. This agreement provides Harvard Bioscience access to hundreds of Fisher Scientific sales representatives who will now offer customers both established product lines—such as pumps and electroporation systems—and access to emerging technologies, including the Mesh MEA (Microelectrode Array) for advanced organoid research.
This strategic expansion marks a significant milestone in Harvard Bioscience’s mission to provide researchers with high-performance, reliable instruments that accelerate scientific discovery. By leveraging Fisher Scientific’s extensive U.S. distribution network and unmatched reputation for customer service, Harvard Bioscience can now deliver even greater convenience and accessibility to its customers across North America.
“Expanding our partnership with Fisher Scientific in the U.S. is a significant step toward providing Harvard Bioscience products to all potential customers throughout the United States,” said John Duke, President & Chief Executive Officer of Harvard Bioscience. “This collaboration enhances the customer experience by providing streamlined ordering, faster delivery, and localized support through a trusted partner.”
With the expanded distribution agreement of Harvard Bioscience’s pumps, spectrophotometers, and electroporation systems to Fisher Scientific’s U.S. catalog, customers can now source a comprehensive range of precision tools from a single vendor — saving valuable time and simplifying procurement processes. The expanded availability ensures that laboratories in both academia and industry can access cutting-edge technologies with the logistical support and purchasing flexibility they expect.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at https://www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenue and gross margin, and matters relating to the Company’s ability to continue as a going concern, fund its operations, or refinance outstanding indebtedness. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
(508) 893-3120
investors@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.